key: cord-0712721-nrwzsvmo authors: Balduzzi, Alberto; Salvia, Roberto; Löhr, Matthias title: Risk stratification tools for branch‐duct intraductal papillary mucinous neoplasms of the pancreas date: 2022-02-05 journal: United European Gastroenterol J DOI: 10.1002/ueg2.12205 sha: 87199217d9999332a1361d1f6aafae1ef5fb4b43 doc_id: 712721 cord_uid: nrwzsvmo nan Branch duct papillary mucinous neoplasms (BD-IPMNs) of the pancreas represent the majority of pancreatic cystic neoplasms (PCNs) diagnosed during routine radiologic examinations and are deemed to have the least likelihood of harboring or developing malignancy. 1 While the true risk of progression and malignant degeneration of presumed BD-IPMN is yet to be untangled, thanks to international scientific efforts, 2 current guidelines 3-5 advise for surveillance also for small pancreatic cysts to detect any signs of progression to malignancy and possibly assessing the best time for surgery, notwithstanding the significant burden on patients and healthcare resources. 6, 7 Indeed, patient selection is crucial both to avoid unnecessary surgery and to recommend surveillance if the risk of disease progression cannot be ruled out. Prediction models have been built to improve the correct identification of high-risk IPMNs and thus the selection of patients for surgery. [8] [9] [10] However, there are currently no tools to recommend the best IPMN surveillance strategy and to distinguish those who might not warrant surveillance at all. 7 In a recently published article, Overbeek et al. 11 12 Therefore, we support the endeavor to improve patient selection and identify those who are at low risk of progression, even more during the current Covid-19 pandemic. However, it is questionable whether the currently available scientific evidence is sufficient to support these findings. Indeed, we will need large international observational series, with long-time surveillance. The DART-1 was built on guidelines published in 2012 13 and will certainly benefit from a refinement centered on the updated 2017 and 2018 guidelines. 3, 4 As an exponential increase in publications focused on IPMNs has occurred in recent years, these latter guidelines would also benefit from updating, which is currently in progress. Recently, Mestier et al. 14 gery in HRI following screening appears to be too broad to be routinely applied. 14 An inspiring shared-decision program has been designed by Scholten et al., 15 focusing on total pancreatectomy for HRIs to develop pancreatic malignancies. What really stands out from this study is the importance of engaging the patient in the decisionmaking process. Not only must the consensus be present among different specialists, but it must also be shared and understood in its risks and benefits by the patient himself. Therefore, if a BD-IPMN is suspected, the physician is required to explain to the patient the risk of surveillance, the possible psychological burden, the need for radiological examinations, the change in progression, and the possibility to shift the management to surgery with its associated risks. Likewise, the patient should be appraised that the indication for lifelong follow-up persists even after surgery because of the risk of recurrence or new cancer in the remaining pancreas. In conclusion, it is all about balance, and balance itself cannot only be referred to as a precise mathematical equation discounting both clinician and patient insights. Future studies should focus on large observational series of presumed BD-IPMN without signs of degeneration, aiming to detect the true radiological and biological dynamic predictors associated with BD-IPMN progression to malignancy. In fact, we cannot rely on a single frame to predict the possible evolution of the BD-IPMN. To date, it does not seem advisable to Review of the diagnosis and management of intraductal papillary mucinous neoplasms. United Verona evidence-based meeting (EBM) 2020 on intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: meeting report Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas European evidence-based guidelines on pancreatic cystic neoplasms. Gut American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts Systematic review and meta-analysis of observational studies on BD-IPMNS progression to malignancy Trivial" cysts redefine the risk of cancer in presumed branch-duct intraductal papillary mucinous neoplasms of the pancreas: a potential target for follow-up discontinuation? A multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-grade dysplasia in intraductal papillary mucinous neoplasms Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression Psychological distress in patients under surveillance for intraductal papillary mucinous neoplasms of the pancreas: the "Sword of Damocles" effect calls for an integrated medical and psychological approach a prospective analysis International Consensus Guidelines 2012 for the management of IPMN and MCN of the pancreas Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level metaanalysis and proposition of the Beaujon score Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables